Ami Vyas1, Zachary Babcock2, Stephen Kogut2. 1. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USA. avyas@uri.edu. 2. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI, 02881, USA.
Abstract
PURPOSE: Cancer diagnosis in adults is often accompanied by negative impacts, which increase the risk of depression thereby lowering health-related quality of life (HRQoL). We examined the association between depression treatment and HRQoL among US adults with cancer and depression. METHODS: Patients age 18 and above, with self-reported cancer and depression diagnoses were identified from Medical Expenditure Panel Survey database for 2006-2013. Baseline depression treatment was categorized as antidepressants only, psychotherapy with or without antidepressant use, and no reported use of antidepressants or psychotherapy. HRQoL was measured using SF-12 physical component summary (PCS) and mental component summary (MCS) scores. Adjusted ordinary least squares regressions estimated the association between type of depression treatment and HRQoL. RESULTS: Out of 450 (weighted per calendar year: 2.1 million) cancer adults included in the study, 51% received antidepressants only, while 16% received psychotherapy with or without antidepressants. In bivariate analyses, the mean MCS score was lowest among those who received psychotherapy with or without antidepressants compared to those receiving antidepressants only and those with no reported use of either modality, p < 0.05. In multivariate analyses, there was no significant difference in HRQoL by type of depression treatment. CONCLUSION: Despite treatment for depression, HRQoL did not improve during the measurement timeframe. Quality of life is a priority health outcome in cancer treatment, yet our findings suggest that current clinical approaches to ameliorate depression in cancer patients appear to be suboptimal. IMPLICATIONS FOR CANCER SURVIVORS: Adults with cancer and comorbid depression should receive appropriate depression care in order to improve their HRQoL.
PURPOSE:Cancer diagnosis in adults is often accompanied by negative impacts, which increase the risk of depression thereby lowering health-related quality of life (HRQoL). We examined the association between depression treatment and HRQoL among US adults with cancer and depression. METHODS:Patients age 18 and above, with self-reported cancer and depression diagnoses were identified from Medical Expenditure Panel Survey database for 2006-2013. Baseline depression treatment was categorized as antidepressants only, psychotherapy with or without antidepressant use, and no reported use of antidepressants or psychotherapy. HRQoL was measured using SF-12 physical component summary (PCS) and mental component summary (MCS) scores. Adjusted ordinary least squares regressions estimated the association between type of depression treatment and HRQoL. RESULTS: Out of 450 (weighted per calendar year: 2.1 million) cancer adults included in the study, 51% received antidepressants only, while 16% received psychotherapy with or without antidepressants. In bivariate analyses, the mean MCS score was lowest among those who received psychotherapy with or without antidepressants compared to those receiving antidepressants only and those with no reported use of either modality, p < 0.05. In multivariate analyses, there was no significant difference in HRQoL by type of depression treatment. CONCLUSION: Despite treatment for depression, HRQoL did not improve during the measurement timeframe. Quality of life is a priority health outcome in cancer treatment, yet our findings suggest that current clinical approaches to ameliorate depression in cancerpatients appear to be suboptimal. IMPLICATIONS FOR CANCER SURVIVORS: Adults with cancer and comorbid depression should receive appropriate depression care in order to improve their HRQoL.
Entities:
Keywords:
Cancer; Depression; Health-related quality of life; Medical Expenditure Panel Survey
Authors: Kathleen Ell; Bin Xie; Brenda Quon; David I Quinn; Megan Dwight-Johnson; Pey-Jiuan Lee Journal: J Clin Oncol Date: 2008-09-20 Impact factor: 44.544
Authors: Gary Rodin; Nancy Lloyd; Mark Katz; Esther Green; Jean A Mackay; Rebecca K S Wong Journal: Support Care Cancer Date: 2006-10-21 Impact factor: 3.603
Authors: D Razavi; J F Allilaire; M Smith; A Salimpour; M Verra; B Desclaux; P Saltel; I Piollet; A Gauvain-Piquard; C Trichard; B Cordier; R Fresco; E Guillibert; D Sechter; J P Orth; M Bouhassira; P Mesters; P Blin Journal: Acta Psychiatr Scand Date: 1996-09 Impact factor: 6.392
Authors: A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: P Jimenez-Fonseca; C Calderón; R Hernández; T Ramón Y Cajal; M Mut; A Ramchandani; O Donnay; A Carmona-Bayonas Journal: Clin Transl Oncol Date: 2018-04-12 Impact factor: 3.405
Authors: Alessandra Babore; Sonia M Bramanti; Lucia Lombardi; Liborio Stuppia; Carmen Trumello; Ivana Antonucci; Alessandra Cavallo Journal: Support Care Cancer Date: 2018-12-19 Impact factor: 3.603
Authors: Jing Du; Matthijs Plas; Anthony R Absalom; Barbara L van Leeuwen; Geertruida H de Bock Journal: J Surg Oncol Date: 2020-01-12 Impact factor: 3.454
Authors: Giuditta Carretti; Daniela Mirandola; Sara Germano; Mirko Manetti; Mirca Marini Journal: Int J Environ Res Public Health Date: 2022-08-04 Impact factor: 4.614
Authors: Lixin Song; Ting Guan; Peiran Guo; Fengyu Song; Courtney Van Houtven; Xianming Tan; Thomas C Keyserling Journal: Cancer Med Date: 2020-08-04 Impact factor: 4.452